drugset / Trial / NCT00317941
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the injection site reaction and injection site pain after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different autoinjectors.
Timeline
- Start
- 2006-03
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Interferon beta-1a | Protein / enzyme biologic | 44 ug | Subcutaneous |
| Subject | Interferon beta-1b | Protein / enzyme biologic | 250 ug | Subcutaneous |